Singular Health Group Ltd (shg) Logo

Singular Health Group Ltd (SHG)

___:___ · Healthcare

SHG Chart


SHG's Principal Activity is the development of Volumetric Rendering Platform ("VRP") and derivative software solutions; Research and development activities; Sales and marketing of MedVR and 3 Dicom products; and Capital Raising

Share Price Activity

Last (Price)
Change 0.00 (0.00)
Bid / Ask -
Volume (4w avg)
Day Range -
Prev Close
Last Trade


1 Week
1 Month
2022 YTD
1 Year
vs Sector (1yr) -
vs ASX 200 (1yr) -44.20%


Market Cap Question Mark Icon
Excludes mandatory escrowed shares and foreign shares.
ASX Rank 2,043 of 2,417
Sector Rank 184 of 210

Key Fundamentals

Shares Issued
Sector Healthcare
Similar Companies VTI / ESE / VIP
EPS -$0.06
DPS $0.00
Book Value Per Share $0.05

Broker Consensus

SHG is not covered by a major broker, or data from most recent compilation was omitted due to not meeting QA guidelines.


Date Heading Pages File Size Time

Corporate Overview

Singular Health Group Ltd (SHG)is a medical technology company that empowers practitioners and patients via personalised surgical planning solutions that drive better health outcomes. Singular Health has developed a proprietary Volumetric Rendering Platform (VRP) that leverages existing 2D radiological images to generate fully immersive patient-specific 3D/VR models.

Incorporation Details

No incorporation details available.

Corporate Details

Head Office Subiaco WA 6008
Registry Automic Group
Auditor Moore Australia Audit (WA)
Date Listed 12 Feb 2021

Upcoming Calendar (Forecasted)

Date Event
30/08/2022 Report (Prelim)
29/09/2022 Report (Annual)
23/02/2023 Report (Interim)

Dividend History

DPS and Yield calculations use the Pay Date.

Ex-Date Amount Franking Gross Type Payable
No dividends paid.

See Upcoming Dividends for all ASX companies.

Directors & Management

Directors & Management

Name Title Since Bio
Mr Andrew Ian Just Non-Executive Director Jan 2021

Mr Andrew Ian Just

Non-Executive Director

Mr Just was employed by Roche Pharmaceuticals as a Health Economist. He built economic models for inclusion of Roche products on the Australian Medical Benefits Scheme and then in GE Healthcare where he was appointed General Manager of Services for Australia and New Zealand. He has since gained over 25 years of senior executive experience in the healthcare industry at Fortune 500 and ASX listed companies including Stryker, Cochlear, GE Healthcare, Radiometer, Roche, and Novartis. Andrew has prior ASX experience having previously been the Chief Executive Officer and Managing Director of ASX listed company Paragon Care Limited (ASX:PGC). He is a member of the Risk committee.

Mr Howard Andrew Digby Non-Executive Chairman,Non-Executive Director Jan 2021

Mr Howard Andrew Digby

Non-Executive Chairman,Non-Executive Director

Mr Digby began his career at IBM and has spent over 25 years managing technology-related businesses in the Asia Pacific region, of which 11 years were spent in Hong Kong. Prior to returning to Perth, Howard was with The Economist Group as Regional Managing Director. He has also held senior regional management roles at Adobe and Gartner. He is Chair of the Risk committee

Dr Kwang Guan Tay Executive Director Feb 2020

Dr Kwang Guan Tay

Executive Director

Prof Tay is Currently an Adjunct Associate Professor at the Faculty of Health and Medical Sciences at the University of Western Australia, Dr Tay has held various academic positions over the past 20 years (primarily in an adjunct or visiting capacity) at the University of Western Australia, as well as Edith Cowan University. Dr Tay has also managed projects at Khalifa University, the premier research-intensive university in Abu Dhabi, the United Arab Emirates.

Mr Denning Sang-Tatt Chong Founder,Non-Executive Director Feb 2020

Mr Denning Sang-Tatt Chong

Founder,Non-Executive Director

Mr Chong has been the principal of James Chong Lawyers since 2004. Denning has had the opportunity to assist across a broad spectrum of the community - from ASX listed companies and cross border type transactions, to local communities. Denning holds positions with various prominent property development companies, including currently being a director of the Australian subsidiaries of a prominent SGX listed property developer, with a property portfolio. He is also a director of a boutique venture capital business focusing on property, financial and medical technology sectors. Denning is one of the founders of Singular Health and was involved in the early stage funding and governance of Singular Health since its incorporation. He is a member of the Risk committee.

Mr Thomas Sylvanus Hanly Chief Executive Officer,Managing Director Feb 2020

Mr Thomas Sylvanus Hanly

Chief Executive Officer,Managing Director

Mr Hanly has understanding of capital markets and an interest in technology, he was heavily involved in the early 2000's driving the development and commercialisation of a financial services start-up in the United States before returning to Australia. Thomas' early career saw him work as an economic analyst for AgricultureNZ before moving to the United States where he obtained his Series 7 and was employed in private banking with Merrill Lynch. Prior to joining Singular Health, Thomas has held a number of board positions of privately held companies in Australia and Singapore and has acted as an independent consultant assisting with the funding and commercialisation of innovative technologies.

Mr Steven Wood Company Secretary N/A

Director Transactions

SHG directors must report any change in shareholding to the ASX within 5 business days.

See Director Transactions for all ASX companies.

Date Director Type Amount Price Value Notes
30/12/21 Thomas Hanly Buy +16,064 $0.295 $4,738 On-market trade

Director Interests

The current holdings of SHG directors.

Director Last Notice Direct Shares Indirect Shares Options Convertibles
Thomas Hanly 30/12/2021 16,065 3,500,000 6,000,000 N/A
Denning Chong 30/06/2021 N/A 4,380,000 4,500,000 N/A
Kwang Tay 30/06/2021 157,398 N/A 3,000,000 N/A
Howard Digby 30/06/2021 50,000 35,000 1,000,000 N/A
Andrew Just 30/06/2021 N/A N/A 1,000,000 N/A

Shareholder Info

Top 20 Shareholders

Data supplied by Morningstar and accurate on Sep 23, 2021.

It's not possible to publish a real-time Top 20 Shareholder list. Companies are not obliged to report this data (with the exception of Substantial Shareholders above 5%). If a company chooses to publish the data, it's usually once a year in their Annual Report.

All data is manually compiled so there might be a delay between the Annual Report being published and the data appearing on Market Index (<7 days for ASX 300 and up to 30 days for micro-caps).

Name Shares Capital
Sim Tek Tan 8,780,000 8.54%
Chong Ling Diamond Cheong 7,065,754 6.87%
Jli Enterprises Pty Ltd <Jli A/C> 4,900,000 4.77%
Jcc Health Pty Ltd<The Jde Medvr A/C> 4,380,000 4.26%
Sylvan Capital Pte Ltd 3,500,000 3.40%
Mr Pak Lim Kong 3,473,973 3.38%
Sc Consultant Pty Ltd 3,161,918 3.08%
Garry Tet Kheng Chong 3,000,000 2.92%
Cs Third Nominees Pty Limited <Hsbc Cust Nom Au Ltd 13 A/C> 2,878,376 2.80%
Peninsula Treescape Pty Ltd <The Cardinals A/C> 2,700,000 2.63%
Sandhurst Trustees Ltd<Cyan C3G Fund A/C> 2,425,000 2.36%
Wang (Aust) Pty Ltd 2,340,000 2.28%
Stained Glass Windows Pty Ltd <The Fast Lane Sf A/C> 2,000,000 1.95%
Fayweng Pty Ltd 2,000,000 1.95%
Mr Philip John Cawood 1,804,795 1.76%
Grange Consulting Group Pty Ltd 1,000,000 0.97%
Mr Lim Pak Kong 1,000,000 0.97%
Jebtai Pty Ltd 1,000,000 0.97%
Richard Tai Pty Ltd 1,000,000 0.97%
Bnp Paribas Nominees Pty Ltd <Ib Au Noms Retailclient Drp> 958,891 0.93%
Lombardi Super Pty Ltd<Lombardi Super Fund A/C> 850,000 0.83%
Royanna Pty Ltd <Royanna Super Fund A/C> 850,000 0.83%
Ausglobal One Pty Ltd 838,974 0.82%
Reenergise Australia Pty Ltd <Jrh Family A/C> 830,000 0.81%
Graham Hugh Moore 800,000 0.78%

Shareholder Distribution

As reported in the most recent Annual Report.

Holding Size 1 - 1,000 1,001 - 5,000 5,001 - 10,000 10,001 - 100,000 100,001+ Total
No. of Shareholders 207 1,033 434 528 90 2,292

Substantial Shareholders

A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.

Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.

Name Last Notice Total Shares Shares Held (%)
Chong Ling Diamond Cheong 23/09/2021 7,065,754 6.87
Sim Tek Tan 23/09/2021 8,780,000 8.54

Shareholders Buying

12 month transaction history compiled from ASX announcements.

No buy transactions reported by Substantial Shareholders in the past 12 months.

Shareholders Selling

12 month transaction history compiled from ASX announcements.

No sell transactions reported by Substantial Shareholders in the past 12 months.

Historical Data

Share Price History

Date Close Change %Chg Open High Low Volume Turnover

Historical Data

Year Closing Price Last Trade
2021 $0.31 30 June
SHG Historical Price Data (CSV)
Up to 20 years of EOD share price history
You must be logged in to access this feature. Please sign up for free or login.
Market Index, ASX and Morningstar Logos

All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.